Zymeworks Inc (OQ:ZYME)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 108 Patriot Drive, Suite A
MIDDLETOWN DE 19709
Tel: N/A
Website: https://www.zymeworks.com
IR: See website
<
Key People
Kenneth H. Galbraith
Chairman of the Board, President, Chief Executive Officer
Christopher Astle
Chief Financial Officer, Senior Vice President
Paul A. Moore
Chief Scientific Officer
Business Overview
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas with an emphasis on developing ADC and multi-specific antibody therapeutics (MSAT) candidates. Its pipeline of preclinical product candidates includes two lead programs, ZW191 and ZW17.
Financial Overview
For the fiscal year ended 31 December 2023, Zymeworks Inc revenues decreased 82% to $76M. Net loss totaled $118.7M vs. income of $124.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Stock-based Compensation in SGA increase from $1.2M to $5.3M (expense), Foreign exchange gain decrease from $1.2M (income) to $1.2M (expense).
Employees: 272 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $352.65M as of Dec 31, 2023
Annual revenue (TTM): $76.01M as of Dec 31, 2023
EBITDA (TTM): -$127.89M as of Dec 31, 2023
Net annual income (TTM): -$118.67M as of Dec 31, 2023
Free cash flow (TTM): -$122.38M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 71,219,441 as of Mar 4, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.